Group B Streptococcus Prophylaxis in the Third Trimester
The recommended approach for Group B Streptococcus (GBS) prophylaxis in the third trimester is universal screening at 35-37 weeks gestation with vaginal-rectal cultures, followed by intrapartum antibiotic prophylaxis for all GBS-positive women during labor. 1, 2
Screening Protocol
- Timing: Screen all pregnant women at 35-37 weeks gestation (optimal window is 36 0/7 to 37 6/7 weeks) 3
- Method: Single swab collection from lower vagina followed by rectum (through anal sphincter) 1
- Special populations requiring screening:
Indications for Intrapartum Antibiotic Prophylaxis
Intrapartum antibiotic prophylaxis is indicated for:
- Positive GBS vaginal/rectal culture at 35-37 weeks gestation
- GBS bacteriuria during current pregnancy (regardless of colony count)
- Previous infant with invasive GBS disease
- Unknown GBS status with:
- Delivery at <37 weeks gestation
- Rupture of membranes ≥18 hours
- Intrapartum fever ≥38°C (100.4°F)
Recommended Antibiotic Regimens
- Penicillin G: 5 million units IV initial dose, then 2.5-3.0 million units IV every 4 hours until delivery
- OR Ampicillin: 2 g IV initial dose, then 1 g IV every 4 hours until delivery
For penicillin-allergic patients 1:
- Without history of anaphylaxis/angioedema/respiratory distress:
- Cefazolin: 2 g IV initial dose, then 1 g IV every 8 hours until delivery
- With history of anaphylaxis/angioedema/respiratory distress:
- If GBS isolate is susceptible: Clindamycin 900 mg IV every 8 hours until delivery
- If GBS isolate is resistant or susceptibility unknown: Vancomycin 1 g IV every 12 hours until delivery
Management of Special Situations
Preterm Labor (<37 weeks)
For women presenting with signs/symptoms of preterm labor 1:
- Obtain vaginal-rectal GBS culture
- Start GBS prophylaxis
- If determined not to be in true labor, discontinue prophylaxis
- If GBS culture results become available and are negative, discontinue prophylaxis
- If patient remains pregnant and reaches 35-37 weeks, repeat screening
Preterm Premature Rupture of Membranes (PPROM)
For women with PPROM 1:
- Obtain vaginal-rectal GBS culture
- Start antibiotics for latency or GBS prophylaxis
- If entering labor, continue antibiotics until delivery
- If not in labor, continue antibiotics per standard of care for latency or for 48 hours if receiving for GBS prophylaxis
Important Clinical Considerations
- Duration of prophylaxis: While 4 hours of antibiotic administration before delivery is optimal, even shorter durations (≥2 hours) have been shown to reduce GBS vaginal colony counts and decrease neonatal sepsis 3
- Pharmacokinetics: Studies show that even with <4 hours of prophylaxis, fetal serum penicillin G levels significantly exceed the minimal inhibitory concentration for GBS, suggesting benefit even in precipitous labors 5
- Oral antibiotics ineffective: Oral antimicrobial agents should not be used to treat GBS colonization during pregnancy as they are ineffective in eliminating carriage or preventing neonatal disease 2
- Previous treatment not sufficient: Women who received treatment for GBS UTI during pregnancy still require intrapartum prophylaxis, as prior treatment does not eliminate the risk of colonization at delivery 2
Common Pitfalls to Avoid
- Treating GBS colonization with oral antibiotics in the third trimester: This approach is ineffective as studies show that 30-70% of treated women remain colonized at delivery 1
- Skipping intrapartum prophylaxis for women previously treated for GBS UTI: These women still require intrapartum prophylaxis as recolonization is common 2
- Delaying necessary obstetric interventions to achieve 4 hours of prophylaxis: Medically necessary interventions should not be delayed solely to provide 4 hours of antibiotics 3
- Failing to perform susceptibility testing for penicillin-allergic patients: This is essential due to increasing resistance to alternative antibiotics 2
By following these evidence-based guidelines, the risk of early-onset GBS disease can be significantly reduced, improving neonatal outcomes and reducing morbidity and mortality.